Literature DB >> 2529220

Presence on a human melanoma of multiple antigens recognized by autologous CTL.

B Van den Eynde1, P Hainaut, M Hérin, A Knuth, C Lemoine, P Weynants, P van der Bruggen, R Fauchet, T Boon.   

Abstract

We derived from blood lymphocytes of a melanoma patient a large number of cytolytic T-cell clones directed against a cell line of the autologous tumor. Three distinct groups of antigens were recognized by these CTL on the autologous melanoma cells: group A consisted of stable antigens present on all sublines, whereas antigens B and C appeared unstable and were expressed by distinct sublines. In vitro immunoselections with various anti-A CTL clones were applied to the melanoma cells and variants resistant to 3 different CTL clones were obtained. These variants remained sensitive to other anti-A CTL clones, indicating that group A comprises at least 4 different antigens (D, E, F and A'). From a total of 76 CTL clones obtained from lymphocytes collected from the patient at various times, we found that 45 were anti-B, 17 were anti-C, 2 were anti-D, 9 were anti-E, 2 were anti-F and I was anti-A'. It is therefore likely that the 6 antigens identified by these CTL clones represent all or nearly all the transplantation antigens recognized by autologous CTL on this human melanoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2529220     DOI: 10.1002/ijc.2910440413

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  45 in total

1.  Identification of novel small molecules that inhibit protein-protein interactions between MAGE and KAP-1.

Authors:  Neehar Bhatia; Bing Yang; Tony Z Xiao; Noel Peters; Michael F Hoffmann; B Jack Longley
Journal:  Arch Biochem Biophys       Date:  2011-01-28       Impact factor: 4.013

Review 2.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

Review 3.  Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.

Authors:  Yvonne Paterson; Patrick D Guirnalda; Laurence M Wood
Journal:  Semin Immunol       Date:  2010-03-17       Impact factor: 11.130

4.  Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.

Authors:  D J Dunnion; A L Cywinski; V C Tucker; A K Murray; A B Rickinson; P Coulie; M J Browning
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

5.  Melanoma vaccines: clinical status and immune endpoints.

Authors:  Deena M Maurer; Lisa H Butterfield; Lazar Vujanovic
Journal:  Melanoma Res       Date:  2019-04       Impact factor: 3.599

Review 6.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

Review 7.  Monoclonal antibodies in cancer therapy.

Authors:  R Gruber; E Holz; G Riethmüller
Journal:  Springer Semin Immunopathol       Date:  1996

Review 8.  Applications of Immunogenomics to Cancer.

Authors:  X Shirley Liu; Elaine R Mardis
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

9.  Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies.

Authors:  Y T Chen; E Stockert; Y Chen; P Garin-Chesa; W J Rettig; P van der Bruggen; T Boon; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

10.  Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model.

Authors:  M Sivanandham; S D Scoggin; N Tanaka; M K Wallack
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.